SAT0396 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2)
SAT0396 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2)